Abeona Therapeutics Inc. ABEO

Company Overview

Abeona Therapeutics Inc. is a U.S.-based clinical-stage biotechnology company focused on developing cell and gene therapies for serious and life-threatening diseases, particularly rare genetic disorders. The company operates within the biotechnology and biopharmaceutical industries, with an emphasis on adeno-associated virus (AAV)-based gene therapies and cell-based therapeutic platforms. Abeona’s primary revenue activity has historically consisted of licensing arrangements, collaboration agreements, and financing activities, as the company has remained primarily focused on research, clinical development, and regulatory advancement rather than large-scale commercial product sales.

The company’s lead program has been EB-101, an autologous gene-corrected cell therapy developed for recessive dystrophic epidermolysis bullosa (RDEB), a rare inherited skin disorder. Abeona has also advanced AAV-based gene therapy candidates targeting ophthalmic and metabolic diseases. Founded in 1974 and later evolving through mergers, restructurings, and biotechnology-focused strategic shifts, Abeona transitioned from earlier business models into a rare disease gene therapy company. Its strategic positioning has centered on orphan disease indications with high unmet medical need, where smaller patient populations may benefit from accelerated regulatory pathways, orphan drug exclusivity, and specialized treatment approaches.